{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:10:18Z","timestamp":1779275418238,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes. Key barriers to vaccine efficacy include tumor immune evasion, heterogeneity and the suppressive tumor microenvironment; combination therapies with checkpoint inhibitors or chemotherapy are evaluated for their potential to overcome these challenges. Despite promising trials, challenges persist in neoantigen selection, biomarker development, regulatory approval and scalable vaccine manufacturing. Data on current global utilization, approved indications and coverage disparities particularly in low and middle-income countries are presented. Furthermore, the cancer vaccine market is segmented by disease type, platform technology and region, with rising investments in personalized mRNA platforms and combined immunotherapies driving growth. In conclusion, cancer vaccines offer a less toxic, more precise approach to cancer prevention and treatment. Continued innovation, global collaboration, and infrastructure development are essential to realizing their full potential in improving patient outcomes and reducing the global cancer burden.<\/jats:p>","DOI":"10.1177\/10781552251375363","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:16:21Z","timestamp":1757344581000},"page":"709-717","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A new frontier in oncology: Understanding the landscape of cancer vaccines"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-0339","authenticated-orcid":false,"given":"Tarun Kumar","family":"Suvvari","sequence":"first","affiliation":[{"name":"Squad Medicine and Research (SMR)"},{"name":"Department of Medicine, Rangaraya Medical College, Kakinada, India"},{"name":"Dr. NTR University of Health Sciences, Vijayawada, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshavi","family":"Killi","sequence":"additional","affiliation":[{"name":"Squad Medicine and Research (SMR)"},{"name":"Kamineni Cancer Centre, Kamineni Hospitals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Veggalam","sequence":"additional","affiliation":[{"name":"Squad Medicine and Research (SMR)"},{"name":"Prathima Institute of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkataramana","family":"Kandi","sequence":"additional","affiliation":[{"name":"Squad Medicine and Research (SMR)"},{"name":"Prathima Institute of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"e_1_3_3_2_2","volume-title":"Global Cancer Observatory: cancer today","author":"Ferlay J","year":"2023","unstructured":"Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer, 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0895"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2023.131225"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125670"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082418"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021002"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02179-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24173142"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.010"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0648-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-014-0328-0"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641307"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02894-y"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09709-1"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112750"},{"key":"e_1_3_3_23_2","first-page":"23","article-title":"Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology","volume":"7","author":"Anugwom CM","year":"2021","unstructured":"Anugwom CM, Allaire M, Akbar SMF, et al. Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 2021; 7: 23.","journal-title":"Hepatoma Res"},{"key":"e_1_3_3_24_2","first-page":"1855","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang MH","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855\u20131859.","journal-title":"Taiwan Childhood Hepatoma Study Group. N Engl J Med"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834010397692"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz8235"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020962050"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202006"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27925"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125670"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.581"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01674-3"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz8235"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0245"},{"key":"e_1_3_3_36_2","unstructured":"Cancer Vaccines Market Size Share & Industry Analysis By Type (Preventive and Therapeutic) By Technology (Molecular-based Vector-based and Cell-based) By Indication (Cervical Cancer Bladder Cancer Prostate Cancer Lung Cancer and Others) By Distribution Channel (Hospitals Government & Organization Supply and Others) and Regional Forecast 2024-2032. Fortune Business Insights. [Internet]. https:\/\/www.fortunebusinessinsights.com\/cancervaccines-market-106958 (2025 accessed 23 June 2025).."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251375363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251375363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251375363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:55:12Z","timestamp":1779274512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251375363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552251375363"],"URL":"https:\/\/doi.org\/10.1177\/10781552251375363","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}